Why the study?
Advances in genetics and pathophysiology have yielded novel targeted therapies that, combined with standard care, may improve outcomes across diverse cardiomyopathies.
This expert consensus document provides a state-of-the-art summary of practical approaches and targeted therapies for the contemporary management of various cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Provides practical cardiomyopathy management guidance; extends prior consensus with targeted contemporary recommendations.
Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.
No takes yet. Share an insight, caveat, or question.
Seferović et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: